Role of Bordetella bronchiseptica in the atrophic rhinitis challenge model used for Rhiniseng® pre-clinical efficacy testing

Trang chủ Tri thức Role of Bordetella bronchiseptica in the atrophic rhinitis challenge model used for Rhiniseng® pre-clinical efficacy testing

Role of Bordetella bronchiseptica in the atrophic rhinitis challenge model used for Rhiniseng® pre-clinical efficacy testing

In this work, the B. bronchiseptica strain to be used for RHINISENG® pre-clinical efficacy testing was characterized in an in vivo model to evaluate its ability to cause atrophic rhinitis lesions by its own.

Giới thiệu về bài báo này

Tác giả

Montané, J.; Monells, M.; Torrents, D.; March, R.; Sitjà, M.; Camprodon, A.

Tóm tắt

The toxigenic Bb strain used in the challenge model for RHINISENG® pre-clinical efficacy testing demonstrated its ability to cause atrophic rhinitis lesions by its own, even more than the toxigenic Pm strain used in this study (Figure 1). It has been described that expression of the dermonecrotic toxin by Bb is not necessary for predisposing to infection with toxigenic Pm, therefore the Bb strain selected for vaccine efficacy testing was more pathogenic than required. Moreover, the infection dose of Bb used in RHINISENG® studies was higher than the commonly used for reproducing non-progressive atrophic rhinitis (NPAR), where one milliliter of a suspension of <1•106 CFU/ml is administered.

Dịch vụ liên quan

Sản phẩm liên quan

Chia sẻ